Emtricitabine and Tenofovir alafenamide

Therapeutic indications

Emtricitabine and Tenofovir alafenamide is indicated for:

Human immunodeficiency virus type 1 infection

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Emtricitabine/tenofovir alafenamide fixed-dose combination is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

200 mg of emtricitabine and 10 or 25 mg of tenofovir alafenamide once daily according to third agent in the HIV treatment regimen

Contraindications

Emtricitabine and Tenofovir alafenamide is contraindicated in the following cases:

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.